clinical trial · NCT07540832
Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
Zhejiang Haichang Biotech Co., Ltd.·phase2·not yet recruiting·n = 80
Advanced Hepatocellular Carcinoma (HCC)WGI-0301WGI-0301Lenvatinb
brief summary
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer.
started
Sep 1, 2026
primary completion
Sep 1, 2028
completion
Oct 1, 2028
last updated
Apr 20, 2026
official title
An Open-Label Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced Hepatocellular Carcinoma as Second Line Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol